AI-generated from publicly available materials.Leeds-based medtech spinout adsilico has secured £10 million in funding to enhance its AI-driven virtual patient technology aimed at optimizing medical device testing.
This Series A investment will enable adsilico to expand its computer-generated patient models, which allow manufacturers to evaluate the performance of implants across diverse populations prior to initiating clinical trials. This innovation seeks to address the shortcomings of traditional medical device testing, where participant demographics often do not reflect the broader patient population that will ultimately use these devices.
According to adsilico's cofounder and CEO, Sheena Macpherson, the lack of representation in clinical trials can lead to patients missing out on life-saving devices or facing uncertainty about their efficacy. The company’s Virtual Chimera platform utilizes generative AI to create virtual anatomical models, enabling manufacturers to assess device performance in a simulated environment that mirrors various demographic factors such as age, sex, and body size.
This technology is expected to significantly enhance the pre-clinical development process, allowing for early identification of design issues and better targeting of subsequent testing. With a reported 13.7% approval rate for complex medical devices entering non-clinical testing, adsilico's approach could streamline the pathway to market and ultimately improve patient outcomes. As the company scales, it aims to set new standards in the realm of in silico testing, potentially transforming how medical devices are developed and validated.